Piper Sandler keeps Buy rating for Zura Bio stock

Published on 10/08/2026 at 16:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Piper Sandler's target is USD 26.00 on October 7, 2026. Zura Bio stock costs EUR 3.52 on October 8, 2026 after EUR 3.72, minus 5.38 percent.

ZURA, KYG9TY5A1016, Illustration mit AI erstellt.

Zura Bio stock was at EUR 3.52 at Lang & Schwarz on October 8, 2026 at 4:06 p.m. CEST, down 5.38 percent versus the prior close of EUR 3.72. Piper Sandler maintained a Buy rating and a USD 26.00 price target for Zura Bio on October 7, 2026, according to Business Insider.

Three milestones shape the setup

On August 11, 2026, Zura Bio reported a second-quarter net loss of USD 26.3 million, or USD 0.21 per share, compared with USD 16.0 million, or USD 0.17 per share, in the same quarter of 2025, according to Yahoo Finance.

On September 11, 2026, Yahoo Finance reported that the TibuSHIELD Phase 2 study had enrolled 247 participants and that cash and equivalents stood at USD 205.1 million as of June 30, 2026. On October 7, 2026, Piper Sandler's USD 26.00 target added a fresh analyst reference to the clinical story.

What dates matter next?

Zura Bio management is scheduled to meet virtually with Oppenheimer on October 12 and October 13, 2026, according to Business Insider. Barron's lists November 18, 2026, as the next quarterly reporting date for Zura Bio, with the third-quarter earnings estimate at a loss of USD 0.20 per share, according to Barron's.

What does the target imply?

The USD 26.00 target is a market view on future clinical value, not a reported operating result. The immediate test is TibuSHIELD, where topline results are expected in the fourth quarter of 2026, while TibuSURE results are expected in the first half of 2027, according to Yahoo Finance. The same report puts second-quarter research and development spending at USD 20.7 million, versus USD 8.7 million a year earlier, showing the cost of advancing the programs before clinical proof.

Cash supports the trial calendar

Cash of USD 205.1 million at June 30, 2026, gives Zura Bio a funding reference as it prepares data from two Phase 2 studies. The company describes its pipeline as centered on tibulizumab, with TibuSHIELD focused on hidradenitis suppurativa and TibuSURE focused on systemic sclerosis, while a third study for polymyalgia rheumatica is planned by year-end 2026.

Stock trades below its prior close

A separate Nasdaq quote was last at USD 3.95 on October 8, 2026 at 10:16 a.m. EDT, against a 52-week range of USD 3.15 to USD 7.44. The Lang & Schwarz quote was EUR 3.52 at 4:06 p.m. CEST on October 8, 2026, versus a prior close of EUR 3.72 and down 5.38 percent. The further course of trading is shown by the continuously updated real-time quote of Zura Bio stock.